Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
The enzyme replacement therapy based on taliglucerase alfa has shown a sustained safety profile accompanied by long-term effectiveness in children with Gaucher disease (GD). The study “Long-term safety and ... Read more
A Swedish group of Gaucher patients showed clinical features never previously reported in this disease — a rapid and repetitive dystonia-like hyperkinetic movement disorder that may be unique to this group of people, researchers ... Read more
Patients with Gaucher disease (GD) exhibit higher levels of several markers of antioxidant defense compared to healthy controls, a finding that highlights the alterations associated with the disease and the ... Read more
Researchers conducted an enzyme replacement therapy study with a group of Gaucher disease patients and found just a small fraction of patients developed anti-drug antibodies. And, no correlation between antibody development and ... Read more
In a study involving an Egyptian cohort of patients with neuronopathic Gaucher disease, researchers observed that patients show diverse clinical outcomes that are markedly different from those exhibited by patients in other countries. The ... Read more
GBA1 mutations underlying Gaucher disease are not a good prognostic factor for the likelihood of patients developing Parkinson’s disease, according to the results of the study “Clinical course and ... Read more